Gyre Therapeutics Inc. - Asset Resilience Ratio

Latest as of September 2025: 12.33%

Gyre Therapeutics Inc. (GYRE) has an Asset Resilience Ratio of 12.33% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read GYRE liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

$19.65 Million

Cash + Short-term Investments

Total Assets

$159.38 Million

All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2024)

This chart shows how Gyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See Gyre Therapeutics Inc. shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Gyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Gyre Therapeutics Inc. market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$19.65 Million	12.33%
Total Liquid Assets	$19.65 Million	12.33%

Asset Resilience Insights

Moderate Liquidity: Gyre Therapeutics Inc. has 12.33% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Gyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio

Compare Gyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Gyre Therapeutics Inc. (2006–2024)

The table below shows the annual Asset Resilience Ratio data for Gyre Therapeutics Inc..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	11.85%	$14.86 Million	$125.41 Million	--
2023-12-31	0.00%	$0.00	$116.54 Million	--
2022-12-31	12.50%	$10.60 Million	$84.75 Million	+8.00pp
2021-12-31	4.50%	$2.50 Million	$55.66 Million	-47.16pp
2020-12-31	51.66%	$48.99 Million	$94.85 Million	-10.74pp
2019-12-31	62.40%	$61.50 Million	$98.55 Million	-8.78pp
2018-12-31	71.18%	$88.91 Million	$124.92 Million	+25.70pp
2017-12-31	45.48%	$17.97 Million	$39.51 Million	+27.63pp
2016-12-31	17.85%	$6.80 Million	$38.09 Million	+12.96pp
2015-12-31	4.89%	$3.40 Million	$69.52 Million	-40.60pp
2014-12-31	45.50%	$50.95 Million	$112.00 Million	+19.55pp
2013-12-31	25.94%	$37.84 Million	$145.87 Million	+3.41pp
2012-12-31	22.53%	$42.72 Million	$189.58 Million	-11.45pp
2011-12-31	33.98%	$87.72 Million	$258.13 Million	+15.65pp
2010-12-31	18.33%	$48.17 Million	$262.79 Million	+9.83pp
2009-12-31	8.50%	$27.16 Million	$319.38 Million	-29.20pp
2008-12-31	37.71%	$37.16 Million	$98.55 Million	+3.72pp
2007-12-31	33.99%	$33.64 Million	$98.96 Million	+18.69pp
2006-12-31	15.29%	$12.45 Million	$81.37 Million	--

pp = percentage points

About Gyre Therapeutics Inc.

NASDAQ:GYRE USA Biotechnology

Market Cap

$751.40 Million

Market Cap Rank

#10644 Global

#2637 in USA

Share Price

$7.80

Change (1 day)

+1.56%

52-Week Range

$6.65 - $11.50

All Time High

$612.86